NCT00158990View on ClinicalTrials.gov

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

July 31, 2007

Conditions
Major DepressionBipolar DisorderUnipolar Depression
Interventions
DRUG

triiodothyronine

DRUG

sertraline

Trial Locations (2)

91120

Hadassah Medical Organisation, Jerusalem

08540

Global Medical Institutes, Princeton

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Hadassah Medical Organization

OTHER

NCT00158990 - Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression. | Biotech Hunter | Biotech Hunter